Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Langer on the Impact of Frontline Immunotherapy in Lung Cancer

August 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).

Dr. Wakelee on Single-Agent Immunotherapy in NSCLC

August 2nd 2018

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses single-agent immunotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Levy on Therapy for Rapidly Progressing NSCLC

August 2nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses therapy options for patients with rapidly progressing non–small cell lung cancer (NSCLC).

Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC

August 1st 2018

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses patient characteristics when considering immunotherapy in stage III non-small cell lung cancer.

EU Panel Backs Frontline Pembrolizumab Combo for Nonsquamous NSCLC

July 30th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of frontline pembrolizumab (Keytruda) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer without EGFR or ALK mutations, regardless of PD-L1 expression.

Frontline Immunotherapy Poses Fresh Dilemma for Sequencing in NSCLC

July 29th 2018

As the checkpoint inhibitors move into the frontline setting for patients with non–small cell lung cancer, the focus has been placed on the duration of therapy and what to do in the second-line setting following progression.

Optimal Sequence of EGFR TKI Therapy for NSCLC Under Investigation

July 29th 2018

Recent positive clinical trial data have provided the oncology community with several sequencing strategies for patients with EGFR-mutant non-small cell lung cancer.

Targeted Therapies on Horizon for RET-Rearranged NSCLC

July 29th 2018

RET is set to join the list of ever-expanding actionable driver mutations for non–small cell lung cancer, as there are now 3 highly effective therapies in development.

Mok Debates First-Line Versus Second-Line TKI Use in Oncogene-Driven NSCLC

July 29th 2018

The use of frontline versus second-line tyrosine kinase inhibitor use is controversial in many oncogene-driven non-small cell lung cancers.

Dr. Wakelee on Recent Advancements in EGFR-Mutant NSCLC

July 28th 2018

Heather Wakelee, MD, associate professor of medicine (oncology) at the Stanford University Medical Center, discussed the latest therapeutic developments in EGFR-mutant non-small cell lung cancer.

Dr. Herbst on Intriguing Immunotherapy Combinations in NSCLC

July 28th 2018

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and professor of pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; associate director for Translational Research, Yale Cancer Center; Disease Aligned Research Team (DART) Leader, Thoracic Oncology Program, Yale Cancer Center, discusses immunotherapy combinations that have potential in non-small cell lung cancer (NSCLC).

Evolving Lung Cancer Landscape Likely to Involve More Basket Trials

July 28th 2018

Vassiliki A. Papadimitrakopoulou, MD, shares insight on how the lung cancer paradigm continues to evolve with the identification of targetable driver mutations, the challenges that remain, and the ongoing clinical trial efforts designed to better reach patients and improve their outcomes.

Checkpoint Inhibition Greatest Success in Recent Years for Locally Advanced NSCLC

July 28th 2018

Checkpoint inhibition following chemoradiation has shown remarkable successes for patients with locally advanced non–small cell lung cancer, after more than 2 decades without major advances.

Immunotherapy Combos Rapidly Evolving for Lung Cancer

July 28th 2018

The past year has witnessed an explosion in immunotherapy combinations for patients with lung cancer, accompanied by a growing knowledge of biomarkers such as PD-L1 and tumor mutation burden; however, an exact standard of care remains elusive.

Dr. Bunn on Immunotherapy Advances in Small Cell Lung Cancer

July 27th 2018

Paul A. Bunn Jr, MD, distinguished professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care

Dr. Reckamp on MET-Targeting Strategies in NSCLC

July 27th 2018

Karen Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, medical director, Clinical Research Operations, professor, Department of Medical Oncology & Therapeutics Research, thoracic oncologist, discusses current and emerging therapeutic strategies to target MET in non-small cell lung cancer.

Durvalumab Approaches EU Approval for Locally Advanced PD-L1+ NSCLC

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy and whose tumors express PD-L1 on ≥1% of tumor cells.

Immunotherapy Requires Precision Medicine Approach for NSCLC

July 27th 2018

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Dr. Langer on Practice-Changing PACIFIC Data in Stage III NSCLC

July 27th 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the practice-changing data from the PACIFIC trial, which evaluated durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy.